sharesgurusharesguru
  • Stocks
  • Ai Screener
  • Sectors
  • Watchlist
LoginSign Up
sharesguru
  • Home
  • Stocks
  • Ai Screener
  • Sectors
  • Watchlist
  • Profile
  • Contact Us
LoginSign Up
sharesguru

Discover the joy of investing.

All the financial data and tools you need, at one place.

Navigation

  • Home
  • Stocks
  • Sectors

Tools

  • Ai Screener
  • Watchlists

Company

  • Contact

Legal

  • Privacy Policy
  • Terms of Service
Copyright © 2025 Knowtilus Technologies Pvt. Ltd.
SummaryLatest NewsSector ComparisonEarnings ReportRevenue & GrowthPeersIncome StatementBalance SheetCash Flow
WANBURY logo

WANBURY - Wanbury Limited Share Price

Pharmaceuticals & Biotechnology
Sharesguru Stock Score

WANBURY

49/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹245.12+11.67(+5.00%)
Market Closed as of Apr 10, 2026, 15:30 IST
Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 80.5% return compared to 10.7% by NIFTY 50.

Technicals: Bullish SharesGuru indicator.

Cons

Momentum: Stock is suffering a negative price momentum. Stock is down -16.4% in last 30 days.

Smart Money: Smart money looks to be reducing their stake in the stock.

Dividend: Stock hasn't been paying any dividend.

Size: It is a small market cap company and can be volatile.

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Sharesguru Stock Score

WANBURY

49/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Valuation

Market Cap730.2 Cr
Price/Earnings (Trailing)16.45
Price/Sales (Trailing)1.15
EV/EBITDA7.88
Price/Free Cashflow-33.31
MarketCap/EBT17.34
Enterprise Value730.2 Cr

Fundamentals

Revenue (TTM)634.49 Cr
Rev. Growth (Yr)23.8%
Earnings (TTM)42.98 Cr
Earnings Growth (Yr)1.2%

Profitability

Operating Margin7%
EBT Margin7%
Return on Equity72.52%
Return on Assets10.38%
Free Cashflow Yield-3%

Growth & Returns

Price Change 1W-3%
Price Change 1M-16.4%
Price Change 6M-9.2%
Price Change 1Y-9.2%
3Y Cumulative Return80.5%
5Y Cumulative Return21.7%
7Y Cumulative Return40.6%
10Y Cumulative Return17.5%

Cash Flow & Liquidity

Cash Flow from Investing (TTM)-51.17 Cr
Cash Flow from Operations (TTM)26.1 Cr
Cash Flow from Financing (TTM)25.73 Cr
Free Cash Flow (TTM)-22.93 Cr
Free Cash Flow/Share (TTM)-6.97

Balance Sheet

Total Assets413.92 Cr
Total Liabilities354.65 Cr
Shareholder Equity59.27 Cr

Capital Structure & Leverage

Debt Ratio0.42
Debt/Equity2.92
Interest Coverage0.14
Interest/Cashflow Ops1.71

Dividend & Shareholder Returns

Shares Dilution (1Y)6.5%
Shares Dilution (3Y)6.7%
Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 80.5% return compared to 10.7% by NIFTY 50.

Technicals: Bullish SharesGuru indicator.

Cons

Momentum: Stock is suffering a negative price momentum. Stock is down -16.4% in last 30 days.

Smart Money: Smart money looks to be reducing their stake in the stock.

Dividend: Stock hasn't been paying any dividend.

Size: It is a small market cap company and can be volatile.

The Good, Bad and Ugly
Growth
Measures how quickly a company is expanding through metrics like revenue growth, earnings growth, and cash flow growth over time. Strong growth can indicate future potential.
Profitability
Shows how efficiently a company turns business activities into profit, using metrics like profit margins, return on equity (ROE), and return on assets (ROA).
Size
Indicates the company's market presence through metrics like market capitalization, total assets, and revenue. Size can influence stability and market influence.
Dilution Rank
Tracks how much the company's shares have increased or decreased over time. Lower dilution means existing shareholders maintain stronger ownership stakes.
Balance Sheet
Evaluates the company's financial health by analyzing assets, debts, and equity. A strong balance sheet indicates financial stability and flexibility.
Momentum
Measures the strength and speed of price movements, showing whether the stock is gaining or losing market favor over different time periods.
Technicals
Analyzes price patterns, trading volumes, and other market indicators to identify potential trading opportunities and market trends.
Smart Money
Tracks the investment activities of institutional investors, hedge funds, and other large financial players who often have deep research capabilities.
Insider Trading
Monitors buying and selling of company shares by executives, directors, and other insiders who may have unique insights into the company's prospects.

Investor Care

Shares Dilution (1Y)6.5%
Earnings/Share (TTM)13.5

Financial Health

Current Ratio1.11
Debt/Equity2.92

Technical Indicators

RSI (14d)41.9
RSI (5d)57.86
RSI (21d)42.96
MACD SignalSell
Stochastic Oscillator SignalHold
SharesGuru SignalBuy
RSI SignalHold
RSI5 SignalHold
RSI21 SignalHold
SMA 5 SignalBuy
SMA 10 SignalBuy
SMA 20 SignalSell
SMA 50 SignalSell
SMA 100 SignalSell

Summary of Latest Earnings Report from Wanbury

Summary of Wanbury's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Share Holdings

Understand Wanbury ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Share Holding Details

Shareholder NameHolding %
EXPERT CHEMICALS (INDIA) PVT LTD34.41%
KINGSBURY INVESTMENTS INC8.67%
SURESH BHATIA3.12%
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED2.07%
SHARMIN NASSER1.33%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Wanbury Better than it's peers?

Detailed comparison of Wanbury against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker
Name
Mkt Cap
Revenue
Price %, 1M
Returns, 1Y
P/E
P/S
Rev 1-Yr
Inc 1-Yr

Sector Comparison: WANBURY vs Pharmaceuticals & Biotechnology

Comprehensive comparison against sector averages

Comparative Metrics

WANBURY metrics compared to Pharmaceuticals

CategoryWANBURYPharmaceuticals
PE16.4533.70
PS1.154.65
Growth12.5 %8 %
0% metrics above sector average
Key Insights
  • 1. WANBURY is NOT among the Top 10 largest companies in Pharmaceuticals.
  • 2. The company holds a market share of 0.1% in Pharmaceuticals.
  • 3. In last one year, the company has had an above average growth that other Pharmaceuticals companies.

Income Statement for Wanbury

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Revenue From Operations4.2%600576500511393367
Other Income25.1%3.492.990.911.512.41.14
Total Income4.2%603579501513395369
Cost of Materials-3.8%278289257305214146
Purchases of stock-in-trade-12.5%151716201123
Employee Expense19.8%1048781756467
Finance costs28.6%372921212333
Depreciation and Amortization0%131312119.759.68
Other expenses7%1241169310193101
Total Expenses4.6%573548510508407387
Profit Before exceptional items and Tax-3.3%3031-9.694.76-12.41-17.97
Exceptional items before tax-104%026-0.5976083
Total profit before tax-47.3%3056-10.2981-12.4165
Current tax-5.860002.270
Deferred tax-1164.5%-6.840.380.11-0.35-2.070.21
Total tax-219.4%-0.980.380.11-0.350.20.21
Total profit (loss) for period-45.5%3156-10.481-12.6164
Other comp. income net of taxes19.9%-0.37-0.710.11.1-0.41-0.39
Total Comprehensive Income-46.3%3055-10.2983-13.0164
Earnings Per Share, Basic-67.2%9.3226.39-6.1826.88-5.0426.9
Earnings Per Share, Diluted-68.2%8.9826.07-6.1826.79-5.0426.9
Description(%) Q/QDec-2025Sep-2025Jun-2025Mar-2025Dec-2024Sep-2024
Revenue From Operations---163172133161
Other Income---0.351.840.841.63
Total Income---164174134163
Cost of Materials---73766177
Purchases of stock-in-trade---3.13.894.713.2
Employee Expense---29262626
Finance costs---7.549.041010
Depreciation and Amortization---3.643.373.323.32
Other expenses---35323133
Total Expenses---150155133155
Profit Before exceptional items and Tax---14191.298.17
Exceptional items before tax---0000
Total profit before tax---14191.298.17
Current tax---05.8600
Deferred tax---0.12-7.060.070.15
Total tax---0.12-1.20.070.15
Total profit (loss) for period---13201.228.02
Other comp. income net of taxes----0.210.05-0.14-0.15
Total Comprehensive Income---13201.087.87
Earnings Per Share, Basic---4.126.180.762.44
Earnings Per Share, Diluted---3.955.980.72.34
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Revenue From Operations4.2%600576500511393367
Other Income25.1%3.492.990.911.512.41.14
Total Income4.2%603579501513395369
Cost of Materials-3.8%278289257305214146
Purchases of stock-in-trade-12.5%151716201123
Employee Expense19.8%1048781756467
Finance costs28.6%372921212333
Depreciation and Amortization0%131312119.759.68
Other expenses7%1241169310193101
Total Expenses4.6%573548510508407387
Profit Before exceptional items and Tax-3.3%3031-9.694.76-12.41-17.97
Exceptional items before tax-00-0.5976083
Total profit before tax-3.3%3031-10.2981-12.4165
Current tax-5.860002.270
Deferred tax-1164.5%-6.840.380.11-0.35-2.0764
Total tax-219.4%-0.980.380.11-0.350.264
Total profit (loss) for period3.4%3130-10.481-12.610.21
Other comp. income net of taxes19.9%-0.37-0.710.051.12-0.44-0.46
Total Comprehensive Income0%3030-10.3583-13.05-0.25
Earnings Per Share, Basic0.4%9.329.29-6.1826.88-5.0426.9
Earnings Per Share, Diluted-2.4%8.989.18-6.1826.79-5.0426.9
Description(%) Q/QDec-2025Sep-2025Jun-2025Mar-2025Dec-2024Sep-2024
Revenue From Operations1.3%162160163172133161
Other Income-2.5%0.180.20.351.840.841.63
Total Income1.9%163160164174134163
Cost of Materials-5.7%677173766177
Purchases of stock-in-trade39%6.064.643.13.894.713.2
Employee Expense10.7%322929262626
Finance costs2.3%7.267.127.549.041010
Depreciation and Amortization1.5%3.743.73.643.373.323.32
Other expenses-8.1%353835323133
Total Expenses1.4%147145150155133155
Profit Before exceptional items and Tax7.1%161514191.298.17
Total profit before tax7.1%161514191.298.17
Current tax-0005.8600
Deferred tax12.7%0.11-0.020.12-7.060.070.15
Total tax12.7%0.11-0.020.12-1.20.070.15
Total profit (loss) for period7.1%161513201.228.02
Other comp. income net of taxes-25%-0.20.04-0.210.05-0.140
Total Comprehensive Income7.1%161513201.088.01
Earnings Per Share, Basic-1.7%4.524.584.126.180.762.44
Earnings Per Share, Diluted-2%4.514.583.955.980.72.44

Balance Sheet for Wanbury

Consolidated figures (in Rs. Crores) /
Description(%) Q/QSep-2025Mar-2025Sep-2024Mar-2024Sep-2023Mar-2023
Cash and cash equivalents--4.065.893.47.221.49
Current investments--0.130000
Total current financial assets--129125968773
Inventories--3838363522
Current tax assets--00---
Total current assets--193190159155122
Property, plant and equipment--190153149147152
Capital work-in-progress--5.38163.01101.61
Goodwill--1101800
Non-current investments--0.022.040.030.020.01
Loans, non-current--00000
Total non-current financial assets--4.066.166.944.24.23
Total non-current assets--220207184189180
Total assets--414397343346304
Borrowings, non-current--16011982950
Total non-current financial liabilities--162121861010
Provisions, non-current--1717161514
Total non-current liabilities--18013810111616
Borrowings, current--1357281164
Total current financial liabilities--157205199227293
Provisions, current--2.563.483.043.572.68
Current tax liabilities--00-1.441.51
Total current liabilities--175220214253320
Total liabilities--355358316368337
Equity share capital--3333333333
Total equity--593928-22.26-32.82
Total equity and liabilities--414397343346304
Standalone figures (in Rs. Crores) /
Description(%) Q/QSep-2025Mar-2025Sep-2024Mar-2024Sep-2023Mar-2023
Cash and cash equivalents13.7%4.484.065.893.47.181.46
Current investments1.1%0.140.130000
Total current financial assets9.4%141129125968773
Inventories21.6%463838363522
Total current assets16.7%225193190159153121
Property, plant and equipment0%190190153149147152
Capital work-in-progress174%135.38163.01101.61
Goodwill-110%0110000
Non-current investments0%0.020.022.040.030.020.01
Loans, non-current-000000
Total non-current financial assets-8.2%3.814.066.166.944.24.23
Total non-current assets5.5%232220207184189180
Total assets10.4%457414397343345302
Borrowings, non-current-10.1%14416011982950
Total non-current financial liabilities-10.6%145162121861010
Provisions, non-current12.5%191717161514
Total non-current liabilities-8.9%16418013810111616
Borrowings, current308.3%501357281164
Total current financial liabilities7.7%169157205199200266
Provisions, current-0.6%2.552.563.483.043.572.68
Current tax liabilities-000-1.441.51
Total current liabilities5.7%185175220214225293
Total liabilities-1.7%349355358316341310
Equity share capital6.2%353333333333
Total equity82.8%1075939283.3-7.26
Total equity and liabilities10.4%457414397343345302

Cash Flow for Wanbury

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Finance costs28.6%37292121--
Change in inventories82.3%-1.66-14.0428-24.88--
Depreciation0%13131211--
Unrealised forex losses/gains3.9%-0.24-0.290.05-0.02--
Adjustments for interest income-61.3%00.380.42-0.67--
Share-based payments109.2%1.14-0.530.860.71--
Net Cashflows from Operations754.4%284.162038--
Interest paid-0.71000--
Interest received-000-0.67--
Income taxes paid (refund)23.2%0.370.180.170.16--
Other inflows (outflows) of cash--0.41000--
Net Cashflows From Operating Activities738.9%263.982038--
Proceeds from sales of PPE-123.3%0.43.580.0611--
Purchase of property, plant and equipment200%491700--
Proceeds from sales of investment property-0.24000--
Proceeds from sales of intangible assets-003.130--
Interest received52.6%0.630.220.270.56--
Other inflows (outflows) of cash-10.3%-3.41-3-12.3-10.77--
Net Cashflows From Investing Activities-195.9%-51.17-16.63-8.840.59--
Proceeds from issuing shares-1%0.030.040.0450--
Proceeds from issuing other equity instruments-120%0600--
Proceeds from issuing debt-101.1%09500--
Proceeds from borrowings-64000--
Repayments of borrowings-001263--
Payments of lease liabilities10.7%3.373.1432.23--
Interest paid0%35351710--
Net Cashflows from Financing Activities78.6%2615-31.99-25.62--
Net change in cash and cash eq.-137.4%0.661.91-21.0313--
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Finance costs3773.5%370.022121--
Change in inventories-120.5%-1.661428-24.88--
Depreciation0%13131211--
Unrealised forex losses/gains--0.2402.56-0.02--
Adjustments for interest income-61.3%00.380.42-0.67--
Share-based payments-1.1400.860.71--
Net Cashflows from Operations743.8%284.22038--
Interest paid-0.71000--
Interest received-000-0.67--
Income taxes paid (refund)23.2%0.370.180.17-0.16--
Other inflows (outflows) of cash--0.41000--
Net Cashflows From Operating Activities727.8%264.022038--
Proceeds from sales of PPE-123.3%0.43.580.0611--
Purchase of property, plant and equipment-49000--
Proceeds from sales of investment property-0.24000--
Interest received52.6%0.630.220.270.56--
Other inflows (outflows) of cash79.4%-3.41-20.43-12.3-10.77--
Net Cashflows From Investing Activities-195.9%-51.17-16.63-8.840.59--
Proceeds from issuing shares-1%0.030.040.0450--
Proceeds from issuing other equity instruments-120%0600--
Proceeds from issuing debt-101.1%09500--
Proceeds from borrowings-64000--
Repayments of borrowings-102.1%0491263--
Payments of lease liabilities-3.37002.23--
Dividends paid-146.7%03.1400--
Interest paid0%35351710--
Net Cashflows from Financing Activities78.6%2615-31.99-25.62--
Net change in cash and cash eq.-136.2%0.661.94-21.0313--

What does Wanbury Limited do?

Pharmaceuticals•Healthcare•Small Cap

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Industry Group:Pharmaceuticals & Biotechnology
Employees:1,491
Website:www.wanbury.com

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

Performance Comparison

WANBURY vs Pharmaceuticals (2021 - 2026)

Although WANBURY is underperforming relative to the broader Pharmaceuticals sector, it has achieved a 13.0% year-over-year increase.